Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute, part of NDORMS have repurposed the approved drug miglustat to successfully slow the progression of multiple myeloma.

Researchers at the Kennedy Institute, part of NDORMS have repurposed the approved drug miglustat to successfully slow the progression of multiple myeloma.

Multiple myeloma is the second most common blood cancer and there is no known cure for it. Patients suffering from the condition have debilitating pain caused by bone damage, show tiredness, and are prone to infections.

The condition leads to the accumulation of plasma cells, a type of white blood cell, in the bone marrow, interfering with the production of normal blood cells. In addition, myeloma cells promote the activity of osteoclasts – bone cells that destroy and remove bone tissue.

Whilst incurable, multiple myeloma is currently managed using either drugs that target the myeloma cells thus reducing the burden on the bone marrow or drugs which reduce the activity of the osteoclasts. Occasionally, treatment will involve a mix of different therapies and/or a bone marrow transplant.

The research led by Professor Nikki Horwood used a commercial drug developed by Oxford GlycoSciences for the treatment of Gaucher disease – miglustat – and showed it to act on both aspects of multiple myeloma, slowing disease progression and alleviating its symptoms. Whilst still not a definitive cure, miglustat has clear benefits over current therapies for myeloma and would keep disease at bay for the 5,000 people diagnosed with multiple myeloma each year in the UK

Professor Horwood said: "This research is an important step towards targeting myeloma bone disease on more than one front, the cancer cells themselves and the bone destroying cells, using only one drug, which is a fantastic improvement for patients. Miglustat is a commercial drug already available on the market thus translation into clinical practice could happen quicker.  We are continuing to investigate Miglustat, and related drugs, in multiple myeloma and this research provides the proof of principle platform we needed for clinical translation."

You can read the full paper here.

 

This work was supported by the Multiple Myeloma Research Foundation (AE, NH, AK), Leukaemia and Lymphoma Research (KX, AE, AC, ES, MH, AR, IR, DSA, NH and AK), Arthritis Research UK (NH, LD), Kennedy Institute Trustees (YV) and the Glycobiology Institute, University of Oxford (GT, RAD and TDB).

Image: Left - Control group shows holes straight through the bone (blue background). Right - in the group treated with miglustat these holes are almost completely absent.

Similar stories

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

NDORMS researchers awarded grant for study on the effects of COVID-19 vaccines on long COVID

A team of NDORMS researchers including Doctor Annika Jödicke and Doctor Victoria Strauss have been awarded NIHR funding to carry out a study into the effects of different COVID-19 vaccines on long COVID.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.